My NCBISign In
Print View 

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Vesco KK, Whitlock EP, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. (Evidence Syntheses, No. 86.)

Bookshelf ID: NBK66100

References

1.
Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force. AHRQ Publication No 11-05157-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
2.
American Cancer Society. Cervical Cancer. Atlanta, GA: American Cancer Society; 2006. [19 April 2011]. Accessed at http://www​.cancer.org​/cancer/cervicalcancer/index.
3.
Saraiya M, Ahmed F, Krishnan S, et al. Cervical cancer incidence in a prevaccine era in the United States, 1998–2002. Obstet Gynecol. 2007;109:360–370. [PubMed: 17267837]
4.
Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical Oncology. 3. Philadelphia, PA: Elsevier Churchill Livingstone; 2004.
5.
Richart RM. Cervical intraepithelial neoplasia. Pathol Annu. 1973;8:301–328. [PubMed: 4583016]
6.
McCredie M, Sharples K, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet. 2008;9:425–434.
7.
Chang AR. Carcinoma in situ of the cervix and its malignant potential: a lesson from New Zealand. Cytopathology. 1990;1:321–328. [PubMed: 2101679]
8.
Kinlen LJ, Spriggs AI. Women with positive cervical smears but without surgical intervention: a follow-up study. Lancet. 1978;2:463–465. [PubMed: 79818]
9.
Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000;78:97–105. [PubMed: 10926787]
10.
Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–2119. [PubMed: 11966386]
11.
Acta Cytol; The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop; April 29–30, 1991; 1993. pp. 115–124.
12.
National Office of Vital Statistics, US Department of Health, Education, and Welfare. Vital Statistics of the United States, 1950 Volume III: Mortality Data. Washington, DC: U.S. Government Printing Office; 1953. [19 April 2011]. Accessed at http://www​.cdc.gov/nchs​/data/vsus/VSUS_1950_3.pdf.
13.
Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. Natl Vital Stat Report. 2007;58:1–135.
14.
International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention: Cervix Cancer Screening. Vol. 10. Lyon, France: IARC Press; 2005.
15.
National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program. SEER Stat Fact Sheets: Cervix Uteri. Bethesda, MD: National Cancer Institute; 2011. [21 April 2011]. Accessed at http://seer​.cancer.gov​/statfacts/html/cervix​.html#incidence-mortality.
16.
Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute; 2011. [21 April 2011]. Accessed at http://www​.seer.cancer​.gov/csr/1975_2008/index.html.
17.
Howlader N, Noone AM, Krapcho M, et al., editors. SEER incidence and U.S. death rates by race/ethnicity: cancer of the cervix uteri, SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute; 2011.
18.
Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;85:791–794. [PMC free article: PMC1615485] [PubMed: 7762711]
19.
Kinney W, Sung HY, Kearney KA, et al. Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC). Gynecol Oncol. 1998;71:428–430. [PubMed: 9887244]
20.
Sung HY, Kearney KA, Miller M, et al. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88:2283–2289. [PubMed: 10820350]
21.
Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System: Prevalence and Trends Data. Atlanta, GA: Centers for Disease Control and Prevention; 2010. [19 April 2011]. Accessed at http://apps​.nccd.cdc.gov/brfss/
22.
Herbert A, Anshu, Culora G, et al. Invasive cervical cancer audit: why cancers developed in a high-risk population with an organised screening programme. BJOG. 2010;117:736–745. [PubMed: 20184570]
23.
Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968. [PMC free article: PMC2718082] [PubMed: 19638651]
24.
Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368–383. [PMC free article: PMC3046952] [PubMed: 21282563]
25.
Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl 1):S1–S15. [PubMed: 16406226]
26.
Munoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527. [PubMed: 12571259]
27.
International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses. Vol. 90. Lyon, France: World Health Organization; 2007.
28.
Bouvard V, Baan R, Straif K, et al. A review of human carcinogens—part B: biological agents. Lancet Oncol. 2009;10:321–322. [PubMed: 19350698]
29.
Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101–105. [PMC free article: PMC2394204] [PubMed: 12838308]
30.
Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–632. [PubMed: 17405118]
31.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. [PubMed: 10451482]
32.
Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942–953. [PMC free article: PMC2409880] [PubMed: 15292939]
33.
Cotton SC, Sharp L, Seth R, et al. Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br J Cancer. 2007;97:133–139. [PMC free article: PMC2359671] [PubMed: 17519896]
34.
Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003–2005. Ann Intern Med. 2008;148:493–500. [PubMed: 18378945]
35.
Berrington de Gonzáles A, Sweetland S, Green J. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885–891. [PubMed: 17131323]
36.
International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119:1108–1124. [PubMed: 16570271]
37.
Appleby P, Beral V, Berrington de Gonzáles A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118:1481–1495. [PubMed: 16206285]
38.
Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303–315. [PubMed: 16507827]
39.
Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case—control study. Cancer Causes Control. 2003;14:805–814. [PubMed: 14682438]
40.
Muñoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002;359:1093–1101. [PubMed: 11943256]
41.
Moreno V, Bosch FX, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085–1092. [PubMed: 11943255]
42.
Cox JT. The development of cervical cancer and its precursors: what is the role of human papillomavirus infection? Curr Opin Obstet Gynecol. 2006;18(Suppl 1):S5–S13. [PubMed: 16520683]
43.
Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007;23:213–227. [PubMed: 17627057]
44.
Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol. 2006;(Suppl):40470. [PMC free article: PMC1581465] [PubMed: 16967912]
45.
Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. [PubMed: 17826171]
46.
Ziegert C, Wentzensen N, Vinokurova S, et al. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene. 2003;22:3977–3984. [PubMed: 12813471]
47.
Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582–1589. [PubMed: 17471427]
48.
Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev. 2007;16:709–715. [PubMed: 17416761]
49.
Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072–1079. [PubMed: 16030305]
50.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 61: human papillomavirus. Obstet Gynecol. 2005;105:905–918. [PubMed: 15802436]
51.
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525–541. [PubMed: 16597322]
52.
De Vuyst H, Lillo F, Broutet N, et al. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17:545–554. [PubMed: 18941376]
53.
Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003:14–19.
54.
Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252–258. [PubMed: 10037103]
55.
Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186–192. [PubMed: 8463044]
56.
Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406–1412. [PubMed: 12824970]
57.
Dalla PP, Giorgi RP, Collina G, et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol. 2009;132:125–132. [PubMed: 19864243]
58.
Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26:441–446. [PubMed: 17885496]
59.
Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18–25. [PMC free article: PMC2694845] [PubMed: 19104355]
60.
National Center for Health Statistics. Health, United States, 2009: with special feature on medical technology. Hyattsville, MD: National Center for Health Statistics; 2010. [19 April 2011]. Accessed at http://www​.cdc.gov/nchs/data/hus/hus09​.pdf.
61.
Centers for Disease Control and Prevention. Cervical Cancer Screening Rates. Atlanta, GA: Centers for Disease Control and Prevention; 2011. [19 April 2011]. Accessed at http://www​.cdc.gov/cancer​/cervical/statistics/screening.htm.
62.
Freeman WP, Wingrove BK. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005. [19 April 2011]. Accessed at http://crchd​.cancer.gov​/attachments/excess-cervcanmort.pdf.
63.
Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675–683. [PubMed: 15870438]
64.
Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680–689. [PubMed: 7702044]
65.
Arbyn M, Antilla A, Jordan J, et al., editors. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2. Luxembourg: European Commission; 2008.
66.
Cytyc Corporation. ThinPrep Pap Test Quick Reference Guide: Endocervical Brush/Spatula Protocol. Boxborough, MA: Cytyc Corporation; 2004. [May 12 2011]. Accessed at http://www​.thinprep.com​/pdfs/pap_quick_reference.pdf.
67.
TriPath Imaging, Inc. SurePath Technology is Changing Cervical Cancer Screening for the Better. Burlington, NC: TriPath Imaging; 2004. [19 April 2011]. Accessed at http://www​.bmpath.com​/documents/Surepath%20Visual%20Sheet​.pdf.
68.
Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–355. [PubMed: 17904957]
69.
American Society for Colposcopy and Cervical Pathology. Management Algorithm for Using HPV Genotyping to Manage HPV High-risk Positive/Cytology Negative Women 30 Years and Older. Hagerstown, MD: American Society for Colposcopy and Cervical Pathology; 2009. [19 April 2011]. Accessed at http://www​.asccp.org​/Portals/9/docs/pdfs​/Consensus%20Guidelines​/hpv_genotyping_20090320.pdf.
70.
Approval Letter: Digene Hybrid Capture 2 High-Risk HPV DNA Test–P890064/S007. Rockville, MD: Center for Devices and Radiological Health, U.S. Food and Drug Administration; 2000.
71.
Approval Letter: Digene Hybrid Capture 2 High-Risk HPV DNA Test–P890064/S009. Rockville, MD: Center for Devices and Radiological Health, U.S. Food and Drug Administration; 2003. [19 April 19, 2011]. Accessed at http://www​.accessdata​.fda.gov/cdrh_docs/pdf/p890064s009a.pdf.
72.
Approval Letter: Cervista HPV High-Risk and Genfind DNA Extraction Kit–P080014. Rockville, MD: Center for Devices and Radiological Health, U.S. Food and Drug Administration; 2009. [19 April 2011]. Accessed at http://www​.accessdata​.fda.gov/cdrh_docs/pdf8/P080014A.pdf.
73.
Approval Letter: Cervista HPV 16/18-080015. Rockville, MD: Center for Devices and Radiological Health, U.S. Food and Drug Administration; 2009. [19 April 2011]. Accessed at http://www​.accessdata​.fda.gov/cdrh_docs/pdf8/P080015A.pdf.
74.
Approval Letter: Cobas HPV Test–P100020. Rockville, MD: Center for Devices and Radiological Health, U.S. Food and Drug Administration; 2011. [11 May 2011]. Accessed at http://www​.accessdata​.fda.gov/cdrh_docs/pdf10/p100020a.pdf.
75.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol. 2008;112:1419–1444. [PubMed: 19037054]
76.
Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120–2129. [PubMed: 11966387]
77.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 109: cervical cytology screening. Obstet Gynecol. 2009;114:1409–1420. [PubMed: 20134296]
78.
Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 1998;92:737–744. [PubMed: 9794661]
79.
Nuovo J, Melnikow J, Willan AR, et al. Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet. 2000;68:25–33. [PubMed: 10687833]
80.
Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2010:CD001318.
81.
Melnikow J, McGahan C, Sawaya GF, et al. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst. 2009;101:721–728. [PMC free article: PMC2684554] [PubMed: 19436026]
82.
Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006;118:2048–2055. [PubMed: 16284947]
83.
Kalliala I, Anttila A, Pukkala E, et al. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ. 2005;331:1183–1185. [PMC free article: PMC1285099] [PubMed: 16293840]
84.
TOMBOLA Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. BMJ. 2009;339:b2546. [PMC free article: PMC2718083] [PubMed: 19638646]
85.
Sharp L, Cotton S, Cochran C, et al. TOMBOLA Group. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG. 2009;116:1506–1514. [PubMed: 19583712]
86.
Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489–498. [PubMed: 16473126]
87.
Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284. [PMC free article: PMC2544379] [PubMed: 18801868]
88.
Werner CL, Lo JY, Heffernan T, et al. Loop electrosurgical excision procedure and risk of preterm birth. Obstet Gynecol. 2010;115:605–608. [PubMed: 20177293]
89.
Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927. [PubMed: 17494925]
90.
Approval Letter: Cervarix. Rockville, MD: Center for Biologics Evaluation and Research, U.S. Food and Drug Administration; 2009. [19 April 2011]. Accessed at http://www​.fda.gov/BiologicsBloodVaccines​/Vaccines/ApprovedProducts/ucm186959​.htm.
91.
Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861–1868. [PubMed: 17544766]
92.
Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–314. [PubMed: 19586656]
93.
Committee on Adolescent Health Care; ACOG Working Group on Immunization. ACOG Committee Opinion No. 344: human papillomavirus vaccination. Obstet Gynecol. 2006;108:699–705. [PubMed: 16946235]
94.
Irwin K, Montano D, Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol. 2006;108:397–409. [PubMed: 16880312]
95.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35. [PubMed: 11306229]
96.
US Preventive Services Task Force. USPSTF Procedure Manual. AHRQ Publication No 08-05118-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
97.
Noorani HZ, Brown A, Skidmore B, Stuart GC. Liquid-based cytology and human papillomavirus testing in cervical cancer screening, Technology Report No 40. Ottawa, Ontario: Canadian Coordinating Office of Health Technology Assessment; 2003.
98.
Medical Services Advisory Committee. Liquid Based Cytology for Cervical Screening MSAC Reference 12a. Canberra: Australia Department of Health and Ageing; 2002.
99.
Hartmann KE, Hall SA, Nanda K, Boggess JF, Zolnoun D. Screening for Cervical Cancer Systematic, Evidence Review No 25. Rockville, MD: Agency for Healthcare Research and Quality; 2002.
100.
Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605–1610. [PubMed: 10235153]
101.
National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence; 2006.
102.
Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25. [PMC free article: PMC305345] [PubMed: 14606960]
103.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558. [PubMed: 12111919]
104.
Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191:105–113. [PubMed: 15295350]
105.
Sigurdsson K, Sigvaldason H. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. Eur J Cancer. 2007;43:769–774. [PubMed: 17236755]
106.
Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831–1836. [PubMed: 11410191]
107.
Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007;335:28. [PMC free article: PMC1910655] [PubMed: 17517761]
108.
Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302:1757–1764. [PubMed: 19861667]
109.
Taylor S, Kuhn L, Dupree W, et al. Direct comparison of liquid-based and conventional cytology in a South African screening trial. Int J Cancer. 2006;118:957–962. [PubMed: 16152600]
110.
Coste J, Cochand-Priollet B, de Cremoux P, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ. 2003;326:733. [PMC free article: PMC152633] [PubMed: 12676841]
111.
Ronco G. In: Questions regarding publication of NTCC study. Vesco KK, editor. Mar 11, 2008.
112.
Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006;98:765–774. [PubMed: 16757701]
113.
Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncology. 2010;11:249–257. [PubMed: 20089449]
114.
Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764–1772. [PubMed: 17919718]
115.
Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. New Engl J Med. 2007;357:1589–1597. [PubMed: 17942872]
116.
ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383–1392. [PubMed: 12824967]
117.
Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncology. 2009;10:672–682. [PubMed: 19540162]
118.
Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. New Engl J Med. 2009;360:1385–1394. [PubMed: 19339719]
119.
Bjerre P, Silfverdal L, Dillner L, et al. A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage. Am J Obstet Gynecol. 2008;199:24–27. [PubMed: 18295172]
120.
Kotaniemi-Talonen L, Anttila A, Malila N, et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer. 2008;44:565–571. [PubMed: 18248809]
121.
Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. New Engl J Med. 2007;357:1579–1588. [PubMed: 17942871]
122.
Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749–1757. [PubMed: 12365959]
123.
Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003;88:1570–1577. [PMC free article: PMC2377109] [PubMed: 12771924]
124.
Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer. 2005;93:575–581. [PMC free article: PMC2361609] [PubMed: 16136031]
125.
Cárdenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, et al. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. Cancer Epidemiol Biomarkers Prev. 2008;17:2865–2871. [PMC free article: PMC2705895] [PubMed: 18843032]
126.
Mayrand MH, Duarte-Franco E, Coutlee F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian Cervical Cancer Screening Trial (CCCaST). Int J Cancer. 2006;119:615–623. [PubMed: 16572425]
127.
Cochand-Priollet B, Le Galès C, de Cremoux P, et al. Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology. Diagn Cytopathol. 2001;24:412–420. [PubMed: 11391824]
128.
de Cremoux P, Coste J, Sastre-Garau X, et al. Efficiency of the Hybrid Capture 2 HPV DNA test in cervical cancer screening: a study by the French Society of Clinical Cytology. Am J Clin Pathol. 2003;120:492–499. [PubMed: 14560561]
129.
Sankaranarayanan R, Chatterji R, Shastri SS, et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer. 2004;112:341–347. [PubMed: 15352050]
130.
Pan Q, Belinson JL, Li L, et al. A thin-layer, liquid-based Pap test for mass screening in an area of China with a high incidence of cervical carcinoma: a cross-sectional, comparative study. Acta Cytol. 2003;47:45–50. [PubMed: 12585030]
131.
Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncology. 2008;9:929–936. [PubMed: 18805733]
132.
Moy LM, Zhao FH, Li LY, et al. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. Int J Cancer. 2010;127:646–656. [PubMed: 19960441]
133.
Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009;101:1612–1623. [PubMed: 19903804]
134.
Anttila A, Kotaniemi TL, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804. [PMC free article: PMC3191726] [PubMed: 20423964]
135.
Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47:864–71. [PubMed: 21334200]
136.
Andersson S, Dillner L, Elfgren K, et al. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. Acta Obstet Gynecol Scand. 2005;84:996–1000. [PubMed: 16167918]
137.
Bergeron C, Jeannel D, Poveda J, et al. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol. 2000;95:821–827. [PubMed: 10831974]
138.
Del Mistro A, Frayle-Salamanca H, Trevisan R, et al. Triage of women with atypical squamous cells of undetermined significance (ASC-US): results of an Italian multicentric study. Gynecol Oncol. 2010;117:77–81. [PubMed: 20116836]
139.
Kitchener HC, Fletcher I, Roberts C, et al. The psychosocial impact of human papillomavirus testing in primary cervical screening—a study within a randomized trial. Int J Gynecol Cancer. 2008;18:743–748. [PubMed: 17944916]
140.
Maissi E, Marteau TM, Hankins M, et al. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ. 2004;328:1293. [PMC free article: PMC420171] [PubMed: 15166066]
141.
McCaffery K, Waller J, Forrest S, et al. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004;111:1437–1443. [PubMed: 15663132]
142.
McCaffery KJ, Irwig L, Turner R, et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. BMJ. 2010;340:b4491. [PMC free article: PMC2827716] [PubMed: 20179125]
143.
Maissi E, Marteau TM, Hankins M, et al. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer. 2005;92:990–994. [PMC free article: PMC2361952] [PubMed: 15785734]
144.
Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(Suppl 10):K29–41. [PubMed: 18847555]
145.
US Preventive Services Task Force. Screening for Cervical Cancer: Recommendations and Rationale. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
146.
Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–428. [PubMed: 9459645]
147.
Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol. 2003;102:765–773. [PubMed: 14551007]
148.
Galaal KA, Deane K, Sangal S, et al. Interventions for reducing anxiety in women undergoing colposcopy. Cochrane Database Syst Rev. 2007:CD006013.
149.
Massad SL, Markwell S, Cejtin HE, et al. Risk of high-grade cervical intraepithelial neoplasia among young women with abnormal screening cytology. J Low Genit Tract Dis. 2005;9:225–229. [PubMed: 16205193]
150.
Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–1765. [PubMed: 15541448]
151.
Lewin SA, Dick J, Pond P, et al. Lay health workers in primary and community health care. Cochrane Database Syst Rev. 2005:CD004015.
152.
Montanari G, Confortini M, Bellomi A, et al. Assessment of specimen adequacy reproducibility: an Italian experience. Diagn Cytopathol. 2003;28:224–226. [PubMed: 12672101]
153.
National Health Service. NHS Cervical Screening Programme: About Cervical Screening. Sheffield UK: NHS Cancer Screening Programmes; 2011. [19 April 2011]. Accessed at http://www​.cancerscreening​.nhs.uk/cervical​/about-cervical-screening.html.
154.
Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167–177. [PubMed: 18165406]
155.
Davey E, Barratt A, Irwig L, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet. 2006;367:122–132. [PubMed: 16413876]
156.
Schiffman M, Solomon D. Screening and prevention methods for cervical cancer. JAMA. 2009;302:1809–1810. [PubMed: 19861676]
157.
Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med. 2006;144:850–855. [PubMed: 16754927]
158.
Dalla PP, Giorgi RP, Collina G, et al. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol. 2008;129:75–80. [PubMed: 18089491]
159.
Mesher D, Szarewski A, Cadman L, et al. Long-term followup of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer. 2010;102:1405–1410. [PMC free article: PMC2865748] [PubMed: 20354519]
160.
Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101:88–99. [PubMed: 19141778]
161.
Arbyn M, Anttila A, Jordan J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening: second edition—summary document. Ann Oncol. 2010;21:448–458. [PMC free article: PMC2826099] [PubMed: 20176693]
162.
Arbyn M, Ronco G, Cuzick J, et al. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer. 2009;125:2489–2496. [PMC free article: PMC2790915] [PubMed: 19626591]
163.
Ronco G, Meijer C. HPV screening: available data and recommendations for clinical practice. Curr Cancer Ther Rev. 2010;6:104–109.
164.
Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624–1632. [PubMed: 14506122]
165.
Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–1101. [PubMed: 16586444]
166.
Arbyn M, Sasieni P, Meijer CJ, et al. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl 3):S78–S89.
167.
Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. [PMC free article: PMC2658827] [PubMed: 18852164]
168.
Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46–52. [PubMed: 12509400]
169.
Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66:10630–10636. [PubMed: 17062559]
170.
Rebolj M, Lynge E. Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. Br J Cancer. 2010;103:310–314. [PMC free article: PMC2920025] [PubMed: 20628384]
171.
Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478–1488. [PMC free article: PMC2950170] [PubMed: 20841605]
172.
Franco EL. Persistent HPV infection and cervical cancer risk: is the scientific rationale for changing the screening paradigm enough? J Natl Cancer Inst. 2010;102:1451–1453. [PubMed: 20841606]
173.
Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280–293. [PubMed: 14970277]
174.
Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN—an update of pooled evidence. Gynecol Oncol. 2005;99:S7–11. [PubMed: 16154623]
175.
Castle PE, Fetterman B, Thomas CJ, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol. 2010;116:76–84. [PubMed: 20567171]
176.
Sherman M, Schiffman M. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2002:102–107.
177.
Schiffman M, Khan MJ, Solomon D, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005;97:147–150. [PubMed: 15657345]
178.
Stoler MH, Castle PE, Solomon D, et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127:335–337. [PubMed: 17276947]
179.
Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol. 2010;134:193–199. [PubMed: 20660320]
180.
Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516–520. [PMC free article: PMC2789446] [PubMed: 18973271]
181.
Benard VB, Eheman CR, Lawson HW, et al. Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995–2001. Obstet Gynecol. 2004;103:564–571. [PubMed: 14990422]
182.
Rebolj M, van Ballegooijen M, Lynge E, et al. Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. BMJ. 2009;338:b1354. [PMC free article: PMC2673344] [PubMed: 19395420]
183.
Sasieni P, Castanon A. Call and recall cervical screening programme: screening interval and age limits. Curr Diagn Pathol. 2006;12:114–126.
184.
Mandelblatt J, Lawrence W, Yi B, et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women: the case for continued screening. Arch Intern Med. 2004;164:245–247. [PubMed: 14769618]
185.
Fahs MC, Mandelblatt J, Schechter C, et al. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med. 1992;117:520–527. [PubMed: 1503355]
186.
Hutchinson ML, Agarwal P, Denault T, et al. A new look at cervical cytology: ThinPrep multicenter trial results. Acta Cytol. 1992;36:499–504. [PubMed: 1636340]
187.
Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol. 1999;180:571–577. [PubMed: 10076130]
188.
Armaroli P, Gallo F, Bellomi A, et al. Do women ≥50 years of age need as much screening as women <50 years after they have had negative screening results? Br J Cancer. 2008;99:239–244. [PMC free article: PMC2480977] [PubMed: 18594534]
189.
Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010;70:8569–8577. [PubMed: 20978200]
190.
Kalliala I, Dyba T, Nieminen P, et al. Mortality in a long-term follow-up after treatment of CIN. Int J Cancer. 2010;126:224–231. [PubMed: 19585576]
191.
Strander B, Andersson-Ellström A, Milsom I, et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ. 2007;335:1077. [PMC free article: PMC2094166] [PubMed: 17959735]
192.
Henley SJ, King JB, German RR, et al. Surveillance of screening-detected cancers (colon and rectum, breast, and cervix)—United States, 2004–2006. MMWR Surveill Summ. 2010;59:1–25. [PubMed: 21102407]
193.
Barnholtz-Sloan J, Patel N, Rollison D, et al. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control. 2009;20:1129–1138. [PubMed: 19253025]
194.
McDougall JA, Madeleine MM, Daling JR, et al. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992–2003. Cancer Causes Control. 2007;18:1175–1186. [PubMed: 17805982]
195.
Strander B, Ryd W, Wallin KL, et al. Does HPV-status 6–12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer. 2007;43:1849–1855. [PMC free article: PMC2933034] [PubMed: 17614272]
196.
Verguts J, Bronselaer B, Donders G, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG. 2006;113:1303–1307. [PubMed: 16978225]
197.
Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1–150. [PubMed: 19891902]
198.
Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111. [PMC free article: PMC2858109] [PubMed: 20334685]
199.
Pretorius RG, Kim RJ, Belinson JL, et al. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis. 2006;10:5–9. [PubMed: 16378026]
200.
Stoler MH, Vichnin MD, Ferenczy A, et al. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer. 2010;128:1354–1362. [PubMed: 20506504]
201.
Arbyn M, Cuzick J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention. Cancer Lett. 2008;278:1–2. [PubMed: 18930588]
202.
Solomon D. Whitlock EP, editor. Personal communication. May 2, 2011.
203.
Saraiya M, Berkowitz Z, Yabroff KR, et al. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med. 2010;170:977–985. [PubMed: 20548011]
204.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927. [PubMed: 17494925]
205.
Brisson M, Van de Velde N, De Wals P, et al. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ. 2007:464–468.
206.
Gök M, Heideman DA, van-Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010;340:c1040. [PMC free article: PMC2837143] [PubMed: 20223872]
207.
American Society for Colposcopy and Cervical Pathology. Algorithms for the 2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests. J Lower Genital Tract Dis. 2007;11:201–222.
208.
National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program. Age-Specific (Crude) Cervical Cancer Incidence Rates By Race. Bethesda, MD: National Cancer Institute; 2011. [21 April 2011]. Accessed at http://seer​.cancer.gov/
209.
Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100:492–501. [PubMed: 18364502]
210.
Ronco G, Cuzick J, Segnan N, et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer. 2007;43:476–480. [PubMed: 17223540]
211.
Ronco G, Brezzi S, Carozzi F, et al. The New Technologies for Cervical Cancer Screening randomised controlled trial: an overview of results during the first phase of recruitment. Gynecol Oncol. 2007;107(Suppl 1):S230–232. [PubMed: 17822751]
212.
Anttila A, Hakama M, Kotaniemi-Talonen L, et al. Alternative technologies in cervical cancer screening: a randomised evaluation trial. BMC Public Health. 2006;6:252. [PMC free article: PMC1621071] [PubMed: 17042938]
213.
Kotaniemi-Talonen L, Nieminen P, Anttila A, et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer. 2005;93:862–867. [PMC free article: PMC2361654] [PubMed: 16189520]
214.
Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004;110:94–101. [PubMed: 15054873]
215.
Elfgren K, Rylander E, Rådberg T, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol. 2005;193:650–657. [PubMed: 16150255]
216.
Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer. 2006;95:56–61. [PMC free article: PMC2360499] [PubMed: 16773068]
217.
Sargent A, Bailey A, Turner A, et al. Optimal threshold for a positive Hybrid Capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol. 2010;48:554–558. [PMC free article: PMC2815647] [PubMed: 20007387]
218.
Sargent A, Bailey A, Almonte M, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98:1704–1709. [PMC free article: PMC2391119] [PubMed: 18392052]
219.
ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393–1400. [PubMed: 12824968]
220.
ASCUS-LSIL Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000;92:397–402. [PubMed: 10700419]
221.
Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study: design, methods and characteristics of trial participants. Acta Cytol. 2000;44:726–742. [PubMed: 11015972]
222.
Solomon D, Schiffman M, Tarone R. ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293–299. [PubMed: 11181776]
223.
American Cancer Society. Cancer Glossary. Atlanta, GA: American Cancer Society; 2008. [12 May 2011]. Accessed at http://www​.cancer.org​/Cancer/CancerGlossary/index.
224.
U.S. Food and Drug Administration. A–Z Subject Index. Rockville, MD: U.S. Food and Drug Administration; 2008. [12 May 2011]. Accessed at http://www​.fda.gov.
225.
Sigurdsson K. Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines. Cytopathology. 2010;21:213–222. [PubMed: 20646020]
226.
Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439–444. [PubMed: 11606114]
227.
Shastri SS, Dinshaw K, Amin G, et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ. 2005;83:186–194. [PMC free article: PMC2624199] [PubMed: 15798842]

Copyright Notice: http://www.ncbi.nlm.nih.gov/books/about/copyright/

Print View 
Cover of Screening for Cervical Cancer
Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Show details

Download

Other titles in these collections

Related information

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > Bookshelf
Write to the Help Desk